These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


257 related items for PubMed ID: 12213404

  • 1. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.
    Joseph A, Louria-Hayon I, Plis-Finarov A, Zeira E, Zakay-Rones Z, Raz E, Hayashi T, Takabayashi K, Barenholz Y, Kedar E.
    Vaccine; 2002 Sep 10; 20(27-28):3342-54. PubMed ID: 12213404
    [Abstract] [Full Text] [Related]

  • 2. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
    McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.
    FEMS Immunol Med Microbiol; 2002 Feb 18; 32(3):179-85. PubMed ID: 11934561
    [Abstract] [Full Text] [Related]

  • 3. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
    McCluskie MJ, Weeratna RD, Davis HL.
    Vaccine; 2001 Mar 21; 19(17-19):2657-60. PubMed ID: 11257405
    [Abstract] [Full Text] [Related]

  • 4. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.
    BMC Res Notes; 2017 Jan 26; 10(1):68. PubMed ID: 28126014
    [Abstract] [Full Text] [Related]

  • 5. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.
    McCluskie MJ, Davis HL.
    Vaccine; 2000 Oct 15; 19(4-5):413-22. PubMed ID: 11027803
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G, Benjamin P, Soita H, Babiuk LA.
    Vaccine; 2008 May 23; 26(22):2680-8. PubMed ID: 18430493
    [Abstract] [Full Text] [Related]

  • 10. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
    Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL.
    FEMS Immunol Med Microbiol; 2001 Dec 23; 32(1):65-71. PubMed ID: 11750224
    [Abstract] [Full Text] [Related]

  • 11. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ, Davis HL.
    J Immunol; 1998 Nov 01; 161(9):4463-6. PubMed ID: 9794366
    [Abstract] [Full Text] [Related]

  • 12. Immunostimulatory DNA is a potent mucosal adjuvant.
    Horner AA, Ronaghy A, Cheng PM, Nguyen MD, Cho HJ, Broide D, Raz E.
    Cell Immunol; 1998 Nov 25; 190(1):77-82. PubMed ID: 9826449
    [Abstract] [Full Text] [Related]

  • 13. A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging.
    Asanuma H, Zamri NB, Sekine S, Fukuyama Y, Tokuhara D, Gilbert RS, Fukuiwa T, Fujihashi K, Sata T, Tashiro M, Fujihashi K.
    Vaccine; 2012 Jan 17; 30(4):803-12. PubMed ID: 22100889
    [Abstract] [Full Text] [Related]

  • 14. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
    Madhun AS, Haaheim LR, Nøstbakken JK, Ebensen T, Chichester J, Yusibov V, Guzman CA, Cox RJ.
    Vaccine; 2011 Jul 12; 29(31):4973-82. PubMed ID: 21600260
    [Abstract] [Full Text] [Related]

  • 15. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
    McCluskie MJ, Weeratna RD, Davis HL.
    Mol Med; 2000 Oct 12; 6(10):867-77. PubMed ID: 11126201
    [Abstract] [Full Text] [Related]

  • 16. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N, Mukherjee S, Das L, Das PK.
    Eur J Immunol; 2003 Jun 12; 33(6):1508-18. PubMed ID: 12778468
    [Abstract] [Full Text] [Related]

  • 17. Effects of different CpG oligodeoxynucleotides with inactivated avian H5N1 influenza virus on mucosal immunity of chickens.
    Fu J, Liang J, Kang H, Lin J, Yu Q, Yang Q.
    Poult Sci; 2013 Nov 12; 92(11):2866-75. PubMed ID: 24135589
    [Abstract] [Full Text] [Related]

  • 18. Liposomal co-encapsulation of a novel gemini lipopeptide and a CpG-ODN induces a strong Th1 response with the co-activation of a Th2/Th17 profile and high antibody levels.
    Reidel IG, Curti CC, Dorémus L, Béré E, Delwail A, Russi RC, Lecron JC, Morel F, García MI, Müller DM, Jégou JF, Veaute CM.
    Vaccine; 2024 Mar 19; 42(8):1953-1965. PubMed ID: 38378388
    [Abstract] [Full Text] [Related]

  • 19. Immunostimulatory sequence oligdeoxynucleotide/cholera toxin B conjugate: a novel allergen-independent intranasal vaccine for allergic rhinitis.
    Won TB, Quan SH, Kim DY, Rhee CS, Lee CH.
    Ann Allergy Asthma Immunol; 2009 Apr 19; 102(4):314-22. PubMed ID: 19441603
    [Abstract] [Full Text] [Related]

  • 20. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
    Singh SM, Alkie TN, Nagy É, Kulkarni RR, Hodgins DC, Sharif S.
    Vaccine; 2016 Sep 14; 34(40):4807-13. PubMed ID: 27543454
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.